金域医学(603882) - 2023 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2023 was ¥2,001,110,411.40, a decrease of 48.63% compared to the same period last year[3] - The net profit attributable to shareholders for Q3 2023 was ¥291,173,710.58, down 63.85% year-on-year[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2023 was ¥69,985,996.77, a decline of 91.35% compared to the previous year[3] - The basic earnings per share for Q3 2023 was ¥0.62, representing a decrease of 64.16% year-on-year[3] - Total operating revenue for the first three quarters of 2023 was CNY 6,309,622,119.42, a decrease from CNY 12,207,913,043.79 in the same period of 2022, representing a decline of approximately 48.3%[18] - Net profit for the third quarter of 2023 was CNY 566,649,689.09, compared to CNY 2,535,154,588.51 in the same quarter of 2022, reflecting a decrease of approximately 77.7%[20] - Earnings per share (EPS) for the third quarter of 2023 was CNY 1.23, down from CNY 5.25 in the same quarter of 2022, a decline of about 76.7%[21] Assets and Liabilities - The total assets at the end of Q3 2023 were ¥12,163,052,448.98, a decrease of 12.44% from the end of the previous year[4] - As of September 30, 2023, the total assets of the company amounted to ¥12,163,052,448.98, a decrease from ¥13,890,707,837.74 as of December 31, 2022, reflecting a decline of approximately 12.43%[15] - The company's current assets totaled ¥8,602,262,763.26, down from ¥10,659,634,227.24, indicating a decrease of about 19.26% year-over-year[15] - The total liabilities decreased to ¥5,000,000,000.00 from ¥5,000,000,000.00, indicating no change in total liabilities[16] - The total liabilities as of the end of the third quarter of 2023 were CNY 3,486,293,957.41, a decrease from CNY 5,015,880,313.01 at the end of the previous year, representing a reduction of approximately 30.6%[20] - The total equity attributable to shareholders of the parent company was CNY 8,475,913,707.57, down from CNY 8,631,454,886.12, indicating a decrease of about 1.8%[20] Cash Flow - The net cash flow from operating activities for the year-to-date period was ¥507,811,141.76, down 61.82% compared to the previous year[3] - In the first three quarters of 2023, the cash inflow from operating activities was approximately ¥7.07 billion, a decrease of 25.5% compared to ¥9.48 billion in the same period of 2022[23] - The net cash outflow from operating activities was ¥507.81 million, down 61.9% from ¥1.33 billion in the previous year[23] - The cash inflow from investment activities was ¥218.53 million, significantly higher than ¥15.22 million in the same period of 2022[24] - The net cash outflow from investment activities was ¥484.14 million, an improvement from a net outflow of ¥614.57 million in the previous year[24] - The cash inflow from financing activities totaled ¥226.21 million, up from ¥121.78 million in the same period of 2022[24] - The net cash outflow from financing activities was ¥912.54 million, compared to a net outflow of ¥739.36 million in the previous year[24] - The total cash and cash equivalents at the end of the period were approximately ¥2.04 billion, down from ¥2.66 billion at the end of the previous year[24] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 23,590[9] Non-Recurring Gains and Expenses - Non-recurring gains for Q3 2023 included a gain from the disposal of a subsidiary amounting to ¥272,127,049.67[6] - Research and development expenses for the third quarter of 2023 were CNY 365,465,783.65, compared to CNY 457,253,763.37 in the same quarter of 2022, a decrease of approximately 20.1%[20] - The company reported an investment income of CNY 262,154,829.22 in the third quarter of 2023, a significant improvement from a loss of CNY 6,969,233.89 in the same quarter of 2022[20] Accounting Changes - The company implemented new accounting standards starting January 1, 2023, affecting the financial statements[25]